相似文献
1
Efficacy of dupilumab in patients with aspirin-exacerbated respiratory disease and previous inadequate response to anti-IL-5 or anti-IL-5Rα in a real-world setting.
J Allergy Clin Immunol Pract. 2021 Jul;9(7):2910-2912.e1. doi: 10.1016/j.jaip.2021.02.020. Epub 2021 Feb 22.
2
IL-5Rα marks nasal polyp IgG4- and IgE-expressing cells in aspirin-exacerbated respiratory disease.
J Allergy Clin Immunol. 2020 Jun;145(6):1574-1584. doi: 10.1016/j.jaci.2020.02.035. Epub 2020 Mar 19.
3
Dupilumab as Add-on Therapy for Chronic Rhinosinusitis With Nasal Polyposis in Aspirin Exacerbated Respiratory Disease.
Am J Rhinol Allergy. 2021 May;35(3):399-407. doi: 10.1177/1945892420961969. Epub 2020 Sep 23.
4
Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP.
BMC Pulm Med. 2022 Jun 28;22(1):258. doi: 10.1186/s12890-022-02046-3.
5
Cost-effectiveness analysis comparing dupilumab and aspirin desensitization therapy for chronic rhinosinusitis with nasal polyposis in aspirin-exacerbated respiratory disease.
Int Forum Allergy Rhinol. 2021 Dec;11(12):1626-1636. doi: 10.1002/alr.22865. Epub 2021 Jul 26.
6
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
7
Dupilumab increases aspirin tolerance in aspirin-exacerbated respiratory disease.
Ann Allergy Asthma Immunol. 2021 Jun;126(6):738-739. doi: 10.1016/j.anai.2021.03.010. Epub 2021 Mar 19.
8
Dupilumab: A Review in Chronic Rhinosinusitis with Nasal Polyps.
Drugs. 2020 May;80(7):711-717. doi: 10.1007/s40265-020-01298-9.
9
Aspirin-exacerbated respiratory disease and current treatment modalities.
Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1291-1300. doi: 10.1007/s00405-016-4273-1. Epub 2016 Aug 18.
10
Canadian real-world study of access and clinical results using dupilumab for chronic rhinosinusitis with polyps.
J Otolaryngol Head Neck Surg. 2022 Apr 25;51(1):17. doi: 10.1186/s40463-022-00570-0.
引用本文的文献
1
[Diagnosis and drug therapy of chronic rhinosinusitis].
HNO. 2025 Apr 16. doi: 10.1007/s00106-025-01635-y.
2
Clinical efficacy and mechanisms of biologics for chronic rhinosinusitis with nasal polyps.
J Allergy Clin Immunol. 2025 May;155(5):1401-1410. doi: 10.1016/j.jaci.2025.03.011. Epub 2025 Mar 23.
3
New insights into the mechanisms of aspirin-exacerbated respiratory disease.
Curr Opin Allergy Clin Immunol. 2025 Feb 1;25(1):41-46. doi: 10.1097/ACI.0000000000001051. Epub 2024 Dec 6.
4
The Possible Roles of IL-4/IL-13 in the Development of Eosinophil-Predominant Severe Asthma.
Biomolecules. 2024 May 2;14(5):546. doi: 10.3390/biom14050546.
5
[Does aspirin therapy after desensitization still have a role in treatment of chronic rhinosinusitis with nasal polyposis in the era of biologics?].
HNO. 2024 Jul;72(7):484-493. doi: 10.1007/s00106-024-01431-0. Epub 2024 Feb 26.
6
Should Biologics Be Used Before Aspirin Desensitization in Aspirin-Exacerbated Respiratory Disease?
J Allergy Clin Immunol Pract. 2024 Jan;12(1):79-84. doi: 10.1016/j.jaip.2023.09.019. Epub 2023 Sep 29.
7
Perioperative mepolizumab in aspirin-exacerbated respiratory disease does not prevent nasal polyp regrowth.
Ann Allergy Asthma Immunol. 2023 Sep;131(3):384-386. doi: 10.1016/j.anai.2023.06.017. Epub 2023 Jun 17.
8
Aspirin-exacerbated respiratory disease: Updates in the era of biologics.
Ann Allergy Asthma Immunol. 2023 Sep;131(3):317-324. doi: 10.1016/j.anai.2023.05.016. Epub 2023 May 22.
9
Monoclonal antibody or aspirin desensitization in NSAID-exacerbated respiratory disease (N-ERD)?
Front Allergy. 2023 Apr 12;4:1080951. doi: 10.3389/falgy.2023.1080951. eCollection 2023.
10
Mechanistic and clinical updates in AERD: 2021-2022.
J Allergy Clin Immunol. 2023 Jun;151(6):1448-1456. doi: 10.1016/j.jaci.2023.03.015. Epub 2023 Mar 24.
本文引用的文献
1
Disconnect between effects of mepolizumab on severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps.
J Allergy Clin Immunol Pract. 2020 May;8(5):1714-1716. doi: 10.1016/j.jaip.2020.01.009. Epub 2020 Jan 15.
2
Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet. 2019 Nov 2;394(10209):1638-1650. doi: 10.1016/S0140-6736(19)31881-1. Epub 2019 Sep 19.
3
Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD.
J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2462-2465.e1. doi: 10.1016/j.jaip.2019.03.044. Epub 2019 Apr 4.
4
Diagnosis and management of NSAID-Exacerbated Respiratory Disease (N-ERD)-a EAACI position paper.
Allergy. 2019 Jan;74(1):28-39. doi: 10.1111/all.13599. Epub 2018 Oct 2.
5
Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
N Engl J Med. 2018 Jun 28;378(26):2486-2496. doi: 10.1056/NEJMoa1804092. Epub 2018 May 21.
6
A retrospective analysis of mepolizumab in subjects with aspirin-exacerbated respiratory disease.
J Allergy Clin Immunol Pract. 2018 May-Jun;6(3):1045-1047. doi: 10.1016/j.jaip.2018.01.038. Epub 2018 Mar 6.
7
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
N Engl J Med. 2017 Jun 22;376(25):2448-2458. doi: 10.1056/NEJMoa1703501. Epub 2017 May 22.
8
Aspirin-Exacerbated Respiratory Disease--New Prime Suspects.
N Engl J Med. 2016 Feb 4;374(5):484-8. doi: 10.1056/NEJMcibr1514013.
9
Mepolizumab treatment in patients with severe eosinophilic asthma.
N Engl J Med. 2014 Sep 25;371(13):1198-207. doi: 10.1056/NEJMoa1403290. Epub 2014 Sep 8.
Zotero 插件